Bull
$7.55
情境價格
$11.660
-0.079 (-0.68%)收盤時
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
Neogen Corp is a good buy right now due to its current price of $11.66 being below the analyst target of $14, indicating a potential upside of 20.3%. Additionally, the company has shown significant improvement in financial performance, with a reduction in net loss to $11.3 million in Q4, compared to a loss of $612.2 million in the previous year. The main risk is the forward P/E ratio of 16, which suggests that while the stock is currently undervalued, it may face challenges in maintaining growth expectations.
Piper Sandler
$14
2026-08-26
Piper Sandler
2026-08-26
目標價
$14
Piper Sandler
$13
2026-08-03
Piper Sandler
2026-08-03
目標價
$13
Guggenheim
$12
2026-01-09
Guggenheim
2026-01-09
目標價
$12
CJS Securities
$10
2025-12-10
CJS Securities
2025-12-10
目標價
$10
Piper Sandler
$5
2025-10-16
Piper Sandler
2025-10-16
目標價
$5
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Latest Ratings and Outlook from Wall Street

Neogen Corporation Reports Q4 and FY26 Financial Results

Neogen Corp Stock Surpasses Analyst Target Price

Neogen Corporation Q4 Fiscal 2026 Earnings Call Highlights

Neogen Reports Q4 2026 Earnings with Strong EPS and Revenue Beat
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Neogen Corp is a good buy right now due to its current price of $11.66 being below the analyst target of $14, indicating a potential upside of 20.3%. Additionally, the company has shown significant improvement in financial performance, with a reduction in net loss to $11.3 million in Q4, compared to a loss of $612.2 million in the previous year. The main risk is the forward P/E ratio of 16, which suggests that while the stock is currently undervalued, it may face challenges in maintaining growth expectations.
7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。